Cambridge Epigenetix raises $88m Series D financing to advance DNA sequencing technology platform
Cambridge Epigenetix (CEGX), a life sciences tools and technology company revolutionising genome sequencing, has announced the signing of an $88 million Series D financing, bringing the total funds raised to date to $146 million. Temasek led the Series D round with participation from new investors including Third Point and existing investors such as GV, New Science Ventures, Ahren Innovation…
Cambridge Epigenetix appoints Professor Mark Dawson as Scientific Advisor
Cambridge Epigenetix (CEGX), a pioneer in the development and application of epigenetic technologies, today announced the appointment of leading epigenetics-based therapeutics specialist, Professor Mark Dawson to its Scientific Advisory Board (SAB). Professor Dawson brings a wealth of experience in the translation of cancer epigenetics research to clinical practice.
Cambridge Epigenetix strengthens leadership team to support development of diagnostics
Cambridge Epigenetix (CEGX), a pioneer in the development and application of epigenetic technologies, announced that it has appointed diagnostic experts, Hayden Jeffreys as Chief Operating Officer (COO) and Dr Joanne Mason as Vice President (VP) of Biomarker Discovery.
Cambridge Epigenetix and NuGEN Technologies parther to combine leading technologies
Cambridge Epigenetix (CEGX) and NuGEN Technologies, leaders in innovative epigenetic technologies, announced that they have entered into a partnership agreement to integrate the CEGX TrueMethyl technology for oxidative bisulfite sequencing (oxBS-Seq) with NuGEN’s innovative NGS library preparation kits.
Cambridge Epigenetix licenses fundamental DNA methylation IP from Boston Children’s Hospital
Cambridge Epigenetix, a pioneer in the development and application of epigenetic technologies, announced that it has entered into an exclusive license agreement with Boston Children’s Hospital giving access to leading-edge DNA profiling technologies, which may hold the key to improved diagnoses and treatment of many diseases, including cancer.
Cambridge Epigenetix establishes Scientific Advisory Board
Cambridge Epigenetix, a pioneer in the development and application of epigenetic technologies, announces the formation of its Scientific Advisory Board (SAB). The SAB comprises experts for Cambridge Epigenetix’s key focus areas, including oncology, liquid biopsy and ageing.
Cambridge Epigenetix announces $21M Series B financing and appoints Dr Geoff Smith as CEO
Cambridge Epigenetix (CEGX), a pioneer in the development of epigenetic sequencing technologies, today announced the close of a $21 million Series B financing and the appointment of Dr. Geoff Smith as CEO.
Cambridge Epigenetix raises $5.5M in Series A funding
Cambridge Epigenetix (CEGX), a UK-based life sciences company, today announced the appointment of Dr Fedja Bobanovic as CEO and the recent completion of a $5.5M Series A financing led by New Science Ventures. Also joining the round were founding investors Syncona Partners and Cambridge Enterprise.